A Double-blind Comparison of Bromperidol and Haloperidol in Newly Admitted Schizophrenic Patients

Abstract

Forty-seven schizophrenic patients randomly assigned to bromperidol or haloperidol in a 28 day double-blind clinical trial showed statistically significant improvement with no differences between the two treatment groups. Extrapyramidal signs were frequent, but other adverse effects were mild; adverse effects were equally distributed between treatment groups.